At the time of writing, Taysha Gene Therapies Inc [TSHA] stock is trading at $1.63, up 8.67%. An important factor to consider is whether the stock is rising or falling in short-term value. The TSHA shares have gain 21.64% over the last week, with a monthly amount drifted -18.91%, and not seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
From an analyst’s perspective:
Taysha Gene Therapies Inc [NASDAQ: TSHA] stock has seen the most recent analyst activity on June 27, 2024, when BMO Capital Markets initiated its Outperform rating and assigned the stock a price target of $5. Previously, Piper Sandler started tracking the stock with Overweight rating on April 09, 2024, and set its price target to $9. On February 01, 2023, downgrade downgraded it’s rating to Hold and revised its price target to $1.50 on the stock. Morgan Stanley downgraded its rating to a Equal-Weight and decreased its price target to $3 on January 27, 2023. Goldman downgraded its rating to a Neutral and reduced its price target to $3 on November 09, 2022. Robert W. Baird started tracking with a Outperform rating for this stock on March 09, 2022, and assigned it a price target of $26. In a note dated March 01, 2022, Wells Fargo initiated an Overweight rating and provided a target price of $25 on this stock.
For the past year, the stock price of Taysha Gene Therapies Inc fluctuated between $1.19 and $4.32. Currently, Wall Street analysts expect the stock to reach $18.67 within the next 12 months. Taysha Gene Therapies Inc [NASDAQ: TSHA] shares were valued at $1.63 at the most recent close of the market. An investor can expect a potential return of 1045.4% based on the average TSHA price forecast.
Analyzing the TSHA fundamentals
According to Taysha Gene Therapies Inc [NASDAQ:TSHA], the company’s sales were 12.87M for trailing twelve months, which represents an -53.57% plunge. Gross Profit Margin for this corporation currently stands at 0.9% with Operating Profit Margin at -6.03%, Pretax Profit Margin comes in at -8.88%, and Net Profit Margin reading is -8.88%. To continue investigating profitability, this company’s Return on Assets is posted at -0.57, Equity is -2.43 and Total Capital is -0.47. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.36.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 1.5300 points at the first support level, and at 1.4300 for the second support level. However, for the 1st resistance point, the stock is sitting at 1.6900, and for the 2nd resistance point, it is at 1.7500.
Ratios To Look Out For
It is important to note that Taysha Gene Therapies Inc [NASDAQ:TSHA] has a current ratio of 5.20. On the other hand, the Quick Ratio is 5.20, and the Cash Ratio is 5.07. Considering the valuation of this stock, the price to sales ratio is 27.42, the price to book ratio is 3.02.
Transactions by insiders
Recent insider trading involved Manning Paul B, 10% Owner, that happened on Jun 27 ’24 when 1.33 million shares were purchased. 10% Owner, Manning Paul B completed a deal on Nov 17 ’23 to buy 100000.0 shares.
